JP2017512211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512211A5 JP2017512211A5 JP2016572221A JP2016572221A JP2017512211A5 JP 2017512211 A5 JP2017512211 A5 JP 2017512211A5 JP 2016572221 A JP2016572221 A JP 2016572221A JP 2016572221 A JP2016572221 A JP 2016572221A JP 2017512211 A5 JP2017512211 A5 JP 2017512211A5
- Authority
- JP
- Japan
- Prior art keywords
- aminocarbonyl
- amino
- propyl
- pharmaceutically acceptable
- methylcarbamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2- (isopropylamino) -3-phenylpropyl (aminocarbonyl) Chemical group 0.000 claims 43
- 150000001875 compounds Chemical class 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 26
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- CBJFCLHGIISKGU-CQSZACIVSA-N N(C1=CC=CC=C1)C(=O)NC(OC[C@@H](CC1=CC=CC=C1)N)=O Chemical compound N(C1=CC=CC=C1)C(=O)NC(OC[C@@H](CC1=CC=CC=C1)N)=O CBJFCLHGIISKGU-CQSZACIVSA-N 0.000 claims 1
- LGINNYTYYKXJBZ-SNVBAGLBSA-N [(2R)-2-amino-3-phenylpropyl] N-(2-amino-2-oxoethyl)carbamate Chemical compound NC(=O)CNC(OC[C@@H](CC1=CC=CC=C1)N)=O LGINNYTYYKXJBZ-SNVBAGLBSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946142P | 2014-02-28 | 2014-02-28 | |
| US61/946,142 | 2014-02-28 | ||
| PCT/KR2015/001915 WO2015130121A1 (en) | 2014-02-28 | 2015-02-27 | Aminocarbonylcarbamate compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018231320A Division JP6595078B2 (ja) | 2014-02-28 | 2018-12-11 | アミノカルボニルカルバメート化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017512211A JP2017512211A (ja) | 2017-05-18 |
| JP2017512211A5 true JP2017512211A5 (2) | 2018-04-05 |
| JP6452731B2 JP6452731B2 (ja) | 2019-01-16 |
Family
ID=54006446
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572221A Active JP6452731B2 (ja) | 2014-02-28 | 2015-02-27 | アミノカルボニルカルバメート化合物 |
| JP2018231320A Active JP6595078B2 (ja) | 2014-02-28 | 2018-12-11 | アミノカルボニルカルバメート化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018231320A Active JP6595078B2 (ja) | 2014-02-28 | 2018-12-11 | アミノカルボニルカルバメート化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9403761B2 (2) |
| EP (2) | EP3110792B1 (2) |
| JP (2) | JP6452731B2 (2) |
| KR (2) | KR102487051B1 (2) |
| CN (2) | CN106458866B (2) |
| AR (1) | AR099581A1 (2) |
| AU (2) | AU2015223579B2 (2) |
| CA (1) | CA2939835C (2) |
| CL (1) | CL2016002165A1 (2) |
| ES (2) | ES2759312T3 (2) |
| MX (2) | MX387796B (2) |
| PL (1) | PL3110792T3 (2) |
| RU (1) | RU2688673C2 (2) |
| TW (2) | TWI698415B (2) |
| WO (1) | WO2015130121A1 (2) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
| TWI698415B (zh) * | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| MY197630A (en) | 2016-09-06 | 2023-06-29 | Sk Biopharmaceuticals Co Ltd | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
| ES2964943T3 (es) | 2016-10-06 | 2024-04-10 | Axsome Malta Ltd | Compuestos de carbamoilfenilalaninol para uso médico |
| BR112019025286A2 (pt) | 2017-06-02 | 2020-06-23 | Jazz Pharmaceuticals Ireland Limited | Métodos e composições para tratamento de sonolência excessiva |
| CN111153863A (zh) * | 2019-12-13 | 2020-05-15 | 浙江工业大学 | 一种合成动物用抗球虫药物妥曲珠利的方法 |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| KR102390194B1 (ko) | 2020-08-03 | 2022-04-25 | 셀라이온바이오메드 주식회사 | 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077289A (en) | 1989-11-30 | 1991-12-31 | Hoechst Roussel Pharmaceuticals Inc. | Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine |
| AU674358B2 (en) * | 1992-10-28 | 1996-12-19 | Toyama Chemical Co. Ltd. | Novel 1,2-benzoisoxazole derivative or its salt and brain -protecting agent comprising the same |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) * | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| JP2006527214A (ja) * | 2003-06-12 | 2006-11-30 | ノボ ノルディスク アクティーゼルスカブ | パラ置換されたフェニルカルバメート |
| US20050080268A1 (en) | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| US7795307B2 (en) * | 2003-10-21 | 2010-09-14 | Colucid Pharmaceuticals, Inc. | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents |
| RU2007119648A (ru) | 2004-10-28 | 2008-12-10 | СК Холдингз Ко. | Способ лечения депрессии |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| EP1890684B1 (en) * | 2005-06-08 | 2013-08-14 | SK Biopharmaceuticals Co., Ltd. | Treatment of sleep-wake disorders |
| ES2344469T3 (es) | 2005-06-22 | 2010-08-27 | Sk Holdings Co., Ltd. | Tratamiento de disfuncion sexual. |
| US7531572B2 (en) * | 2006-07-28 | 2009-05-12 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use |
| CN101631770A (zh) * | 2007-02-02 | 2010-01-20 | 科露西德医药品公司 | 抑制胆碱酯酶的化合物 |
| KR20120098578A (ko) | 2009-06-22 | 2012-09-05 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| BR112012010670A2 (pt) * | 2009-11-06 | 2016-04-12 | Sk Biopharmaceuticals Co Ltd | métodos para tratamento de distúrbio de défict de atenção/hiperatividade |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| CA2917702A1 (en) * | 2013-07-18 | 2015-01-22 | Jazz Pharmaceuticals International Iii Limited | Treatment for obesity |
| TWI698415B (zh) * | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
-
2015
- 2015-02-25 TW TW108106172A patent/TWI698415B/zh active
- 2015-02-25 TW TW104106005A patent/TWI655179B/zh not_active IP Right Cessation
- 2015-02-26 AR ARP150100575A patent/AR099581A1/es active IP Right Grant
- 2015-02-27 RU RU2016136193A patent/RU2688673C2/ru active
- 2015-02-27 EP EP15754658.1A patent/EP3110792B1/en active Active
- 2015-02-27 MX MX2020003020A patent/MX387796B/es unknown
- 2015-02-27 PL PL15754658T patent/PL3110792T3/pl unknown
- 2015-02-27 JP JP2016572221A patent/JP6452731B2/ja active Active
- 2015-02-27 MX MX2016010973A patent/MX2016010973A/es active IP Right Grant
- 2015-02-27 US US14/633,388 patent/US9403761B2/en active Active
- 2015-02-27 ES ES15754658T patent/ES2759312T3/es active Active
- 2015-02-27 KR KR1020217031464A patent/KR102487051B1/ko active Active
- 2015-02-27 AU AU2015223579A patent/AU2015223579B2/en active Active
- 2015-02-27 KR KR1020167022646A patent/KR102309903B1/ko active Active
- 2015-02-27 CN CN201580010772.6A patent/CN106458866B/zh active Active
- 2015-02-27 CA CA2939835A patent/CA2939835C/en active Active
- 2015-02-27 ES ES19188405T patent/ES2968840T3/es active Active
- 2015-02-27 CN CN201811495363.1A patent/CN109627186B/zh active Active
- 2015-02-27 WO PCT/KR2015/001915 patent/WO2015130121A1/en not_active Ceased
- 2015-02-27 EP EP19188405.5A patent/EP3587394B1/en active Active
-
2016
- 2016-06-28 US US15/195,326 patent/US9833432B2/en active Active
- 2016-08-26 CL CL2016002165A patent/CL2016002165A1/es unknown
-
2017
- 2017-11-07 US US15/805,293 patent/US10314808B2/en active Active
-
2018
- 2018-12-11 JP JP2018231320A patent/JP6595078B2/ja active Active
-
2019
- 2019-04-26 US US16/395,422 patent/US10485781B2/en active Active
- 2019-09-25 AU AU2019236666A patent/AU2019236666B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512211A5 (2) | ||
| RU2016136193A (ru) | Аминокарбонилкарбаматные соединения | |
| JP2017518334A5 (2) | ||
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JP2013508279A5 (2) | ||
| JP2018021051A5 (2) | ||
| RU2018106914A (ru) | 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция | |
| JP2019501130A5 (2) | ||
| JP2012525393A5 (2) | ||
| JP2013534248A5 (2) | ||
| JP2008521827A5 (2) | ||
| JP2015518055A5 (2) | ||
| JP2013518050A5 (2) | ||
| JP2012505836A5 (2) | ||
| JP2013545785A5 (2) | ||
| JP2016532667A5 (2) | ||
| JP2014500265A5 (2) | ||
| JP2014511892A5 (2) | ||
| JP2014508804A5 (2) | ||
| JP2016534063A5 (2) | ||
| AR061584A1 (es) | Uso de 2-aminotetralinas sustituidas para la fabricacion de un medicamento para la prevencion, alivio y/o tratamiento de diversos tipos de dolor | |
| JP2008509166A5 (2) | ||
| JP2020507589A5 (2) | ||
| ES2887042T1 (es) | Moduladores del receptor S1P para el tratamiento de la esclerosis múltiple | |
| JP2019516739A5 (2) |